QEI
HAE icon

QSV Equity Investors’s Haemonetics HAE Stock Holding History

QSV Equity Investors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.12M Sell
14,034
-6,756
-32% -$454K 1.66% 16
2025
Q3 		$1.01M Hold
20,790
– – 1.04% 54
2025
Q2 		$1.55M Buy
+20,790
New +$1.38M 1.62% 19

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

QSV Equity Investors's HAE Position: Q4 2025 in Review

QSV Equity Investors reduced its Haemonetics (HAE) stake by 32% in Q4 2025, selling an estimated $454K and leaving 14,034 shares worth $1.12M. The position accounts for 1.66% of the portfolio, ranked #16.

QSV Equity Investors first reported a position in HAE in Q2 2025 and has held it in 3 quarters since. The position peaked at $1.55M in Q2 2025. 328 funds tracked by Wall St. Rank hold HAE as of Q4 2025.

  • QSV Equity Investors held 14,034 shares of Haemonetics worth $1.12M as of Q4 2025.
  • QSV Equity Investors sold 6,756 Haemonetics shares in Q4 2025, an estimated $454K.
  • Haemonetics made up 1.66% of QSV Equity Investors's portfolio in Q4 2025, its #16 holding.
  • QSV Equity Investors first reported a position in Haemonetics in Q2 2025 and has held it in 3 quarters since.
  • QSV Equity Investors's Haemonetics position peaked at $1.55M in Q2 2025.
  • 328 funds tracked by Wall St. Rank held Haemonetics as of Q4 2025.

Based on QSV Equity Investors's 13F filing for Q4 2025, filed 12 Feb 2026.